Icecure Medical is trading 5.36% up at $2.06 as U.S. equities, technology stocks, and cryptocurrency rally on falling oil prices and lower Treasury yields.

  • No new company-specific announcement was identified for September 21, 2026.
  • The latest major catalyst was September 10 China NMPA approval for ProSense.
  • The approval enables marketing in China but predates today’s move.